Department of Neurology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Interventional Neurology and Neuroradiology, Boston Medical Center, Boston, MA, 02118, USA.
J Neurol. 2022 Feb;269(2):603-608. doi: 10.1007/s00415-021-10734-z. Epub 2021 Jul 31.
We have demonstrated in a multicenter cohort that the COVID-19 pandemic has led to a delay in intravenous thrombolysis (IVT) among stroke patients. Whether this delay contributes to meaningful short-term outcome differences in these patients warranted further exploration.
We conducted a nested observational cohort study of adult acute ischemic stroke patients receiving IVT from 9 comprehensive stroke centers across 7 U.S states. Patients admitted prior to the COVID-19 pandemic (1/1/2019-02/29/2020) were compared to patients admitted during the early pandemic (3/1/2020-7/31/2020). Multivariable logistic regression was used to estimate the effect of IVT delay on discharge to hospice or death, with treatment delay on admission during COVID-19 included as an interaction term.
Of the 676 thrombolysed patients, the median age was 70 (IQR 58-81) years, 313 were female (46.3%), and the median NIHSS was 8 (IQR 4-16). Longer treatment delays were observed during COVID-19 (median 46 vs 38 min, p = 0.01) and were associated with higher in-hospital death/hospice discharge irrespective of admission period (OR per hour 1.08, 95% CI 1.01-1.17, p = 0.03). This effect was strengthened after multivariable adjustment (aOR 1.15, 95% CI 1.07-1.24, p < 0.001). There was no interaction of treatment delay on admission during COVID-19 (p = 0.65). Every one-hour delay in IVT was also associated with 7% lower odds of being discharged to home or acute inpatient rehabilitation facility (aOR 0.93, 95% CI 0.89-0.97, p < 0.001).
Treatment delays observed during the COVID-19 pandemic led to greater early mortality and hospice care, with a lower probability of discharge to home/rehabilitation facility. There was no effect modification of treatment delay on admission during the pandemic, indicating that treatment delay at any time contributes similarly to these short-term outcomes.
我们在一项多中心队列研究中表明,COVID-19 大流行导致中风患者的静脉溶栓(IVT)延迟。这种延迟是否导致这些患者的短期预后存在有意义的差异,值得进一步探讨。
我们对来自美国 7 个州的 9 家综合卒中中心的接受 IVT 的成年急性缺血性卒中患者进行了嵌套观察队列研究。将大流行前(2019 年 1 月 1 日至 2 月 29 日)入院的患者与大流行期间(2020 年 3 月 1 日至 7 月 31 日)入院的患者进行比较。采用多变量逻辑回归估计 IVT 延迟对出院至临终关怀或死亡的影响,将 COVID-19 期间入院的治疗延迟作为交互项。
在 676 名接受溶栓治疗的患者中,中位年龄为 70 岁(IQR 58-81 岁),313 名为女性(46.3%),NIHSS 中位数为 8 分(IQR 4-16 分)。COVID-19 期间观察到更长的治疗延迟(中位数为 46 分钟 vs 38 分钟,p=0.01),无论入院时间如何,住院期间死亡/临终关怀出院的比例均较高(每小时增加 1 小时,OR 1.08,95%CI 1.01-1.17,p=0.03)。多变量调整后,这种影响得到了加强(aOR 1.15,95%CI 1.07-1.24,p<0.001)。COVID-19 期间入院治疗延迟无交互作用(p=0.65)。IVT 每延迟 1 小时,出院至家庭或急性住院康复机构的几率也降低 7%(aOR 0.93,95%CI 0.89-0.97,p<0.001)。
COVID-19 大流行期间观察到的治疗延迟导致早期死亡率和临终关怀率增加,出院回家/康复机构的可能性降低。大流行期间入院治疗延迟没有改变作用,表明任何时候的治疗延迟都会对这些短期预后产生类似的影响。